{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:40:27Z","timestamp":1768707627586,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.bone.2010.11.003","type":"journal-article","created":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T04:40:23Z","timestamp":1289450423000},"page":"578-587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic\/blastic prostate cancer lesion"],"prefix":"10.1016","volume":"48","author":[{"given":"Mandeep S.","family":"Virk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhang","family":"Alaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank A.","family":"Petrigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arion F.","family":"Chatziioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Stout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Dougall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay R.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bone.2010.11.003_bb0005","first-page":"277","article-title":"Cancer Statistics","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bone.2010.11.003_bb0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bone.2010.11.003_bb0015","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0020","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.juro.2008.04.140","article-title":"Histopathological assessment of prostate cancer bone osteoblastic metastases","volume":"180","author":"Roudier","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.bone.2010.11.003_bb0025","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2106\/00004623-200206000-00022","article-title":"The role of growth factors in the repair of bone. Biology and clinical applications","volume":"84-A","author":"Lieberman","year":"2002","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.bone.2010.11.003_bb0030","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/08977190412331279890","article-title":"Bone morphogenetic proteins","volume":"22","author":"Chen","year":"2004","journal-title":"Growth Factors"},{"key":"10.1016\/j.bone.2010.11.003_bb0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1196\/annals.1346.006","article-title":"BMP signaling and skeletogenesis","volume":"1068","author":"Li","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.bone.2010.11.003_bb0040","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0736-0266(02)00095-5","article-title":"Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone","volume":"21","author":"Lee","year":"2003","journal-title":"J Orthop Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0045","first-page":"389","article-title":"Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer","volume":"46","author":"Bobinac","year":"2005","journal-title":"Croat Med J"},{"key":"10.1016\/j.bone.2010.11.003_bb0050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jcb.10679","article-title":"Bone morphogenetic protein signaling in prostate cancer cell lines","volume":"91","author":"Brubaker","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bone.2010.11.003_bb0055","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/bjc.1998.658","article-title":"Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies","volume":"78","author":"Autzen","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bone.2010.11.003_bb0060","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/pros.10193","article-title":"Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer","volume":"54","author":"Masuda","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.bone.2010.11.003_bb0065","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1359\/JBMR.050802","article-title":"Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer","volume":"20","author":"Feeley","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0070","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/pros.2990240406","article-title":"Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells","volume":"24","author":"Harris","year":"1994","journal-title":"Prostate"},{"key":"10.1016\/j.bone.2010.11.003_bb0075","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1158\/0008-5472.CAN-05-0289","article-title":"Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells","volume":"65","author":"Yang","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0080","first-page":"5022","article-title":"Growth regulation of human prostate cancer cells by bone morphogenetic protein-2","volume":"57","author":"Ide","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0085","first-page":"1129","article-title":"Bone morphogenetic proteins and their receptor signaling in prostate cancer","volume":"22","author":"Ye","year":"2007","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.bone.2010.11.003_bb0090","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1016\/j.juro.2009.01.098","article-title":"Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway","volume":"181","author":"Ye","year":"2009","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.bone.2010.11.003_bb0095","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1593\/neo.91836","article-title":"Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment","volume":"12","author":"Morrissey","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.bone.2010.11.003_bb0100","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.1158\/0008-5472.CAN-05-1891","article-title":"Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism","volume":"65","author":"Dai","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1196\/annals.1346.005","article-title":"BMP and BMP inhibitors in bone","volume":"1068","author":"Rosen","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.bone.2010.11.003_bb0110","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature01245","article-title":"Structural basis of BMP signalling inhibition by the cystine knot protein Noggin","volume":"420","author":"Groppe","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bone.2010.11.003_bb0115","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1359\/jbmr.060706","article-title":"Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration","volume":"21","author":"Feeley","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","article-title":"RANK ligand as a therapeutic target for bone metastases and multiple myeloma","volume":"34","author":"Roodman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bone.2010.11.003_bb0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1358\/dot.2002.38.2.820105","article-title":"The role of osteoclastic activity in prostate cancer skeletal metastases","volume":"38","author":"Keller","year":"2002","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.bone.2010.11.003_bb0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bone.2010.11.003_bb0135","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bone.2010.11.003_bb0140","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10555-006-9021-3","article-title":"The RANK\/RANKL\/OPG triad in cancer-induced bone diseases","volume":"25","author":"Dougall","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.bone.2010.11.003_bb0145","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D","article-title":"Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases","volume":"92","author":"Hofbauer","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2010.11.003_bb0150","first-page":"1637","article-title":"Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma","volume":"61","author":"Michigami","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.1199","article-title":"RANK ligand is a prerequisite for cancer-associated osteolytic lesions","volume":"198","author":"Kitazawa","year":"2002","journal-title":"J Pathol"},{"key":"10.1016\/j.bone.2010.11.003_bb0160","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ucl.2004.01.001","article-title":"Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician","volume":"31","author":"Higano","year":"2004","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.bone.2010.11.003_bb0165","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0305-7372(03)00071-9","article-title":"Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment","volume":"29","author":"Eaton","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bone.2010.11.003_bb0170","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.23775","article-title":"Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database","volume":"113","author":"Hatoum","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2010.11.003_bb0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3816\/CGC.2005.n.009","article-title":"Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer","volume":"4","author":"Saad","year":"2005","journal-title":"Clin Prostate Cancer"},{"issue":"3","key":"10.1016\/j.bone.2010.11.003_bb0180","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1359\/jbmr.090810","article-title":"Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure","volume":"25","author":"Body","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0185","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/pros.20744","article-title":"RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model","volume":"68","author":"Ignatoski","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.bone.2010.11.003_bb0190","first-page":"7883","article-title":"Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0195","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2008.09.009","article-title":"Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK\/RANKL axis in osteolytic prostate cancer lesion in bone","volume":"44","author":"Virk","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.003_bb0200","first-page":"5564","article-title":"Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model","volume":"62","author":"Lee","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0205","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.orthres.2005.05.004.1100230634","article-title":"The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone","volume":"23","author":"Whang","year":"2005","journal-title":"J Orthop Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0210","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/1535-7163.MCT-08-0046","article-title":"RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis","volume":"7","author":"Miller","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bone.2010.11.003_bb0215","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0220","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2010.11.003_bb0225","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar2169","article-title":"Tumor metastasis to bone","volume":"9","author":"Virk","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bone.2010.11.003_bb0230","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1158\/0008-5472.CAN-05-1317","article-title":"Prostate cancer cells promote osteoblastic bone metastases through Wnts","volume":"65","author":"Hall","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.11.003_bb0235","doi-asserted-by":"crossref","unstructured":"Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000;44: 91-103 Jul 1;44(2).","DOI":"10.1002\/1097-0045(20000701)44:2<91::AID-PROS1>3.3.CO;2-C"},{"key":"10.1016\/j.bone.2010.11.003_bb0240","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.107.045666","article-title":"Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model with using 18F-FDG and 18F-fluoride PET\/CT","author":"Hsu","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bone.2010.11.003_bb0245","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bone.2005.07.015","article-title":"Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions","volume":"38","author":"Feeley","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.003_bb0250","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/mthe.2001.0423","article-title":"Development of an MFG-based retroviral vector system for secretion of high levels of functionally active human BMP4","volume":"4","author":"Peng","year":"2001","journal-title":"Mol Ther"},{"key":"10.1016\/j.bone.2010.11.003_bb0255","first-page":"633","article-title":"Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET","volume":"33","author":"Hawkins","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bone.2010.11.003_bb0260","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/jcb.20522","article-title":"A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell\u2013microenvironment interactions","volume":"96","author":"Loberg","year":"2005","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bone.2010.11.003_bb0265","doi-asserted-by":"crossref","first-page":"6285s","DOI":"10.1158\/1078-0432.CCR-06-0813","article-title":"Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis","volume":"12","author":"Vessella","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.bone.2010.11.003_bb0270","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.bone.2010.03.001","article-title":"Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis","volume":"46","author":"Canon","year":"2010","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bone.2010.11.003_bb0275","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/cbt.9.7.11266","article-title":"Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L\/TRAIL\/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis","volume":"9","author":"Holland","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.bone.2010.11.003_bb0280","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2353\/ajpath.2007.051276","article-title":"Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases","volume":"170","author":"Schwaninger","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bone.2010.11.003_bb0285","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.eururo.2005.12.045","article-title":"Natural history and treatment of bone complications in prostate cancer","volume":"49","author":"Saad","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.bone.2010.11.003_bb0290","first-page":"308","article-title":"Tumor\u2013bone cellular interactions in skeletal metastases","volume":"4","author":"Chirgwin","year":"2004","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.bone.2010.11.003_bb0295","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cncr.11129","article-title":"Role of endothelin-1 in osteoblastic bone metastases","volume":"97","author":"Guise","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2010.11.003_bb0300","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00259-002-0850-1","article-title":"Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease","volume":"29","author":"Berger","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821002034X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821002034X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:37:54Z","timestamp":1762659474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632821002034X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S875632821002034X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2010.11.003","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic\/blastic prostate cancer lesion","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2010.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}